http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/RSS.ashxAlk Corporate Brochure 2008 PagesFri, 27 Jun 2008 14:04:42 +0200http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1Company brochure Fighting the cause of allergy www.alk-abello.com2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=2http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=22 ALK Fighting the cause of allergy2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=3http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=3ALK Fighting the cause of allergy 3 Company brochure Fighting the cause of allergy Contents 5 6 10 13 15 16 18 19 20 21 23 24 26 31 Allergy is treatable Mission, Vision & Values Meet GRAZAX®-patient Tina Weikel Pioneering allergy research ALK is world leader The need for allergy vaccination Tablet-based allergy vaccination Sublingual allergy vaccination Subcutaneous allergy vaccination Diagnostics and adrenaline Meet Alutard SQ®-patient David Jenkins Join ALK Milestones in the history of ALK ALK addresses2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=4http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=44 ALK Fighting the cause of allergy “Our prime interest is to improve quality of life for people with allergies” Jens Bager, Chief Executive Officer, ALK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=5http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=5ALK Fighting the cause of allergy 5 Allergy is treatable ALK’s allergy vaccines target the allergy itself – providing sustained symptom prevention Allergy is an overreaction of the immune system to substances that are otherwise harmless. The most common allergies are caused by everyday, airborne particles such as pollen or house dust mites. For many people, these tiny particles are insignificant. But for people with allergy, they can trigger seasonal or chronic respiratory conditions, such as hay fever or asthma. Allergy significantly reduces people’s quality of life. It affects not only their personal, but also their professional lives. Coping with itching eyes and a blocked nose has its costs for the individual, but also for society in terms of poorer quality of life, lower productivity levels at work and increased sick leave – not to mention the cost of healthcare and medication. While the majority of allergy patients are exclusively offered medication to relieve the symptoms of the allergy, such medication does not treat the allergy itself. And, most patients find that it has no effect, or at best only a moderate effect, on their symptoms. This is the finding of a survey conducted by the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). Allergy is treatable ALK is committed to improving the quality of life for allergy sufferers by developing products that target the allergy itself, rather than just relieving its symptoms. Allergy vaccination is a well documented therapy, recognized by the World Health Organization as the only truly effective treatment for allergic diseases. The therapeutic principle underlying allergy vaccination is to administer controlled doses of protein substances (allergens) to which the patient is allergic in order to rebuild the immune response tolerance. In this way, the allergic reaction can be reduced and potentially eliminated altogether. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. But at ALK, our aim is to extend the use of allergy vaccination by introducing convenient tabletbased vaccines – offering more patients the option of a causal allergy treatment. Following this strategy, we launched the world’s first tablet-based vaccine for grass pollen allergy, GRAZAX®, in Europe in 2006. In addition, we have a number of innovative new products in our pipeline. We continuously update specialists and general practitioners around the world with the latest information about this new generation of allergy vaccines. In this brochure, we invite you to learn more about ALK and our efforts to improve the quality of life for people with allergies. Jens Bager Chief Executive Officer, ALK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=6http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=66 ALK Fighting the cause of allergy Mission We improve quality of life by preventing and curing allergy Vision • Weareacompanycharacterised by significant and profitable growth • Intheglobalmarketforspecific allergy treatment, we hold the leading position through own representation and partnerships • Ourfutureissecuredbyastrong pipeline. We continuously launch new convenient products providing value for patients and society  • Wearedrivenbycustomer focus and a strong performance culture. We attract and retain dynamic and business-minded employees Values Progressive Focused United Trustworthy These four values describe the company’s culture and internal code of conduct, and also provide broad guidelines for the successful growth of ALK. Internally, the values enhance and empower our organisation and its people. Externally, they are reflected in our communication with customers, investors and other stakeholders.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=7http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=7ALK Fighting the cause of allergy 72008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=8http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=88 ALK Fighting the cause of allergy2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=9http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=9ALK Fighting the cause of allergy 9 ALK’s four values: Progressive, Focused, United, Trustworthy “Being progressive is seeking new opportunities with a flexible attitude. This enables us to succeed in our pursuit and adapt to possible changes, thereby leading the way for our professional and personal development” Anabel Huescar, Sales Representative, ALK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=10http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1010 ALK Fighting the cause of allergy Tina Weikel is one of the first patients to benefit from GRAZAX® - the first registered allergy tablet to address the underlying cause of grass pollen allergy “A happy feeling” Interview with Tina Weikel, GRAZAX®-patient Tina is a typical example of the ‘allergic march’. She suffered from eczema (dermatitis), already in her early childhood. One morning, she woke up with difficulties in breathing, swollen eyes and blocked nose, and her doctor concluded that she suffered from grass pollen allergy. Tina started on eye drops, nasal spray and antihistamine tablets, but none of it really helped. During high school, she found out that she also suffered from allergic asthma. At the same time, Tina’s allergies got worse and her eczema had spread to her face, neck, chest and arms. - It was very difficult, especially during spring and summer. When all my friends were outside having the greatest time of their life, I often sat in my room and didn’t want to show myself, says Tina. In the spring of 2002, Tina became a mother, and in the following years her allergies got even worse. - The summer of 2005 was like hell. My son needed to get outside and play, and I was only allowed to take two antihistamine tablets a day. But I often took five, sometimes eight, and it didn’t help, says Tina. After that summer, it was enough for Tina. She went to see her doctor again. The doctor told her that she was going to do a clinical trial with GRAZAX® and that Tina could be part of the trial. Tina saw this chance as her last hope and she volunteered for the study. In March 2006, she started on GRAZAX® treatment. - Already in July the same year, I was able to cut my own lawn, which simply hadn’t been possible before, says Tina. Today, she hardly has any grass allergy symptoms and GRAZAX® also has a positive effect on symptoms from other allergies. In addition, Tina’s use of symptomatic medication has been drastically reduced. Now she only takes a few antihistamines when visiting her sister who has a cat. - This year was even better than last year. I tested myself and went outside in my garden. I laid down on the grass, and I didn’t have any symptoms at all. It was a happy feeling, says Tina.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=11http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=11ALK Fighting the cause of allergy 11 “It was very difficult, especially during spring and summer. When all my friends were outside having the greatest time of their life, I often sat in my room and didn’t want to show myself” Tina Weikel, Sweden2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=12http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1212 ALK Fighting the cause of allergy ALK’s four values: Progressive, Focused, United, Trustworthy “Being trustworthy is to convey our research results accurately yet in an interesting fashion. Reliable allergy research will shape the future of allergy treatment” Kaare Meno, Researcher, ALK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=13http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=13ALK Fighting the cause of allergy 13 Pioneering allergy research ALK’s history dates back to 1923 when the first allergen extracts were produced at the pharmacy of the Copenhagen University Hospital Since 1923, researchers at ALK have focused on mapping the mechanisms of allergic impact on the immune system in order to develop new and constantly improved allergy therapies. More recently, the focus has been on clinical documentation of the many therapeutic benefits of allergy vaccination. A long series of articles in scientific publications document that ALK’s allergy vaccines significantly reduce allergic symptoms and thereby improve quality of life. This effect is sustained after the completion of treatment. Focusing on the patient’s needs In the 1990’s, ALK was the first company to launch sublingual immunotherapy (allergy vaccination administered as droplets under the tongue). This was a decisive step towards making allergy vaccination more user-friendly. Since then, ALK’s principal research and development strategy has been aimed at introducing tablet-based allergy vaccines. A breakthrough was made in 2006 when the company launched GRAZAX® – the first registered allergy tablet to address the underlying cause of grass pollen allergy. ALK’s future product pipeline also includes development of tablets against house dust mite, ragweed, cat and tree pollen allergy. Preventing future allergies Allergic diseases may even come in a series called the ‘allergic march’. A proportion of adults and children with one type of allergy will progress to other allergy types or even asthma later in life. Thus, the development of allergic diseases can be a life-long struggle. Several studies have shown that allergy vaccination reduces the risk of developing additional allergies and asthma. Allergy vaccination remains the only way to stop the allergic march. The World Health Organisation recognises allergy vaccination as the only approach that targets the cause of allergy and alters the natural course of the disease. The benefits that can be gained from allergy vaccination are reflected in the ARIA (Allergic Rhinitis and its Impact on Asthma) treatment guidelines, which recommend early treatment in the disease process in order to prevent further development of allergic rhinitis and/or asthma. ALK’s researchers were the first to map the 3-dimensional structure of one of the world’s most important allergens, Der p1. The discovery was published as a cover article in the acknowledged scientific publication, The Journal of Immunology.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=14http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1414 ALK Fighting the cause of allergy ALK’s four values: Progressive, Focused, United, Trustworthy Being united is important to me as project coordinator. We have a saying that “the job is done when the last man crosses the line” Djam Yaghin, Project Coordinator, ALK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=15http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=15ALK Fighting the cause of allergy 15 ALK is the world leader in allergy vaccination All of ALK’s allergy vaccines conform to the highest production and quality standards. Comprehensive analyses and quality control at all stages of the manufacturing process, from raw material to final allergy vaccine, ensure standardised quality from batch to batch Allergy vaccines are produced from natural allergen sources such as grass pollen, being harvested at ALK’s raw materials production facility in the USA. After primary purification and quality control, the raw material is subjected to secondary purification of the active pharmaceutical ingredient at automated production facilities in Denmark, France, Spain and the USA. Here, excipients are added and the active pharmaceutical ingredient is formulated as either sublingual droplets, injection-based vaccines or tablets. Following rigorous quality control, the final stages of the production process commence, these being packaging, labelling and distribution. The entire production process is subject to ongoing quality assurance in compliance with current European and American standards for good manufacturing practice. Number of citations per year. Source: ISI Web of Science, February 2008 Number 1 in scientific impact ALK, 934 citations Number 1 in market share: 32% (by January 2008) Number 1 in turnover: EUR 221 million (2007 financial year) Number 1 in R&D investments: EUR 44 million (2007 financial year) Stallergènes, 261 citations Number 1 in patients treated: Allergopharma, 255 citations Europe USA Other countries Total (in 2007) 450,000 750,000 50,000 1,250,000 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 20072008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=16http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1616 ALK Fighting the cause of allergy The need for allergy vaccination Allergy vaccination provides sustained symptom prevention and reduces the risk of developing asthma Antihistamines and nasal corticosteroids (symptomatic medication) have traditionally been cornerstones in the management of allergic rhinitis. Allergic rhinitis has been primarily managed from a symptom relief perspective, i.e. reducing or stopping symptoms with little to no attention on the need to treat the underlying cause of the disease. Despite receiving symptomatic therapies, millions of allergy sufferers experience continual symptoms during the pollen season, limiting their activities and resulting in a poor quality of life. A survey of the burden of allergic rhinitis in Europe showed that despite a diagnosis confirming allergic rhinitis, 83% of subjects felt their condition was a significant health problem because of the burden of symptoms and its impact on general well-being and healthrelated quality of life. In children, symptoms can manifest themselves into learning difficulties. Children with allergic rhinitis may have school problems including absence and poor performance. In addition, sleep disturbance often leads to daytime fatigue and poor concentration in school, resulting in learning impairment. Furthermore, patients with unmanaged allergic rhinitis are at risk of developing asthma. and that 82% of the patients treated with GRAZAX® feel ‘better’ or ‘much better’ in the first treatment season compared with previous seasons. In addition, a significant effect on asthma symptoms is observed in a clinical trial with children. The asthma symptoms included are: coughing, wheezing, chest tightening/shortness of breath and exercise induced symptoms. The children also experience a considerable reduction in the number of days with asthma symptoms. 2 for 1, allergy and asthma benefits Allergy vaccination is a unique approach to allergy management as it treats the underlying cause of the allergy, provides sustained symptom prevention and has been shown to reduce the risk of developing asthma. The preventive effects of allergy vaccination are well documented and this may create a significant opportunity for GRAZAX®, the first tablet-based allergy vaccine. The efficacy and safety of GRAZAX® have been acknowledged in the largest clinical study programme ever conducted within allergy vaccination. The studies show, amongst other things, that the effect of GRAZAX® starts from the very first day of the first grass pollen season under treatment,2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=17http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=17ALK Fighting the cause of allergy 172008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=18http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=1818 ALK Fighting the cause of allergy Tablet-based allergy vaccination As the first company to introduce tablet-based allergy vaccines, ALK has demonstrated its leadership position within immunotherapy innovation. In 2006, GRAZAX® became available to patients as the first registered allergy tablet to address the underlying cause of grass pollen allergy. Tablets are a convenient and popular way for patients to take treatment and it is expected that the launch of tablet vaccines will allow many more patients suffering from allergy to benefit from allergy vaccination. Additional studies of GRAZAX® have been conducted in order to obtain regulatory approval of the tablet as a treatment for children and young people. ALK’s product pipeline also includes tablets against house dust mite, ragweed, cat and tree pollen allergy. GRAZAX® GRAZAX® is a fast-dissolving, once daily allergy vaccination tablet for home treatment of grass pollen allergy. Data shows that 82% of patients treated with GRAZAX® felt ‘better’ or ‘much better’ in the first treatment season compared with previous seasons. ALK has obtained favourable results from a long-term study with GRAZAX® supporting expectations of a long lasting progressive effect after completion of treatment. This helps to distinguish GRAZAX® from the traditional, symptomatic allergy medication which only limits symptoms, whereas GRAZAX® holds the potential to cure the patient’s allergic disorder.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=19http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=19ALK Fighting the cause of allergy 19 Sublingual allergy vaccination Sublingual immunotherapy (SLIT) is allergy vaccination administered as droplets under the tongue, absorbed through the oral mucosa. Studies confirm that sublingual immunotherapy generally relieves symptoms while reducing the patient’s consumption of symptom relieving medication. The use of SLIT products is rapidly rising and their popularity is related to convenience and a sound safety profile, enabling patients to treat themselves and avoid the regular doctor’s appointments required for injection-based allergy vaccination. SLITone® SLITone® is the first droplet-based allergy vaccine for daily administration via a single-dose container. The new form of treatment is more user-friendly as the single-dose containers ensure correct dosage and can be kept at room temperature. This provides greater safety and flexibility for patients, many of whom are children. SLITone® is available in around 40 different species and mixes including different strains of pollens and house dust mites.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=20http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=2020 ALK Fighting the cause of allergy Subcutaneous allergy vaccination Subcutaneous immunotherapy (SCIT) is the injection-based form of allergy vaccine. In this field, ALK has devoted 30 years of experience in maintaining its position as global market leader with the allergy vaccine Alutard SQ®. The injection-based allergy vaccine is a three-year treatment where the patient receives injections of the very allergen to which he or she is allergic. Injections are administered approximately every six weeks. Studies have shown that subcutaneous immunotherapy significantly reduces the risk of developing asthma and additional allergies. ALK markets injection-based allergy vaccines against many types of allergy including respiratory allergy for grass and tree pollen, house dust mites and animal dander. Subcutaneous immunotherapy is also effective for the prevention of severe allergic reactions caused by stinging insects. Several hundred deaths in Europe and the USA every year are caused by insect sting anaphylaxis. Many of these deaths could have been prevented with the use of immunotherapy. Alutard SQ® Alutard SQ® is ALK’s leading product for subcutaneous allergy vaccination. After 30 years on the market, this is still the most frequently used injection-based allergy vaccine in Europe. ALK’s position as market leader has been achieved through sustained clinical research, for instance resulting in more than 60 scientific publications on Alutard SQ®.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=21http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=21ALK Fighting the cause of allergy 21 Diagnostics and adrenaline Allergy diagnostics Optimal allergy treatment requires a specific diagnosis as the basis for a specific treatment of the actual cause of the patient’s allergy. As a supplement to the therapeutic products, ALK manufactures allergen extracts for allergy testing, such as skin-prick tests (Soluprick SQ). Emergency allergy treatment Patients suffering from food allergy or untreated allergy to insect venom may be at risk of experiencing a severe allergic reaction called anaphylaxis, if exposed to the allergen by accident. In such cases the recommended emergency treatment is an intra-muscular injection of adrenaline followed by an immediate call for medical assistance. Adrenaline works directly on the cardiovascular and respiratory systems, reversing the potentially fatal effects by rapidly narrowing the blood vessels to maintain blood pressure, relaxing muscles in the lungs to improve breathing, reversing swelling and stimulating the heart beat. ALK is the physician’s preferred partner in the management of anaphylaxis, providing education and relevant information for patients and carers. EpiPen® EpiPen® is an auto-injector containing adrenaline (epinephrine) and is used for emergency treatment of severe allergic reactions such as those caused by food allergy, insect venom allergy or drug allergy. An adrenaline pen is designed to enable patients to administer the injection themselves.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=22http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=2222 ALK Fighting the cause of allergy “I woke up in the middle of the night with the horrible feeling that I was going to die, unable to catch my breath” David Jenkins, UK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=23http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=23ALK Fighting the cause of allergy 23 Allergy vaccination with Alutard SQ® is a 3-year treatment based on subcutaneous injections. For David Jenkins, it has given him a freedom to be himself “Allergy vaccination changed my life” Interview with David Jenkins, Alutard SQ®-patient Now 38 years old, David Jenkins has suffered from hay fever since the age of 19. At times, hay fever made David’s life a misery. – I used to dread the summer months, I felt like I had the flu, says David Jenkins. Along with all the usual hay fever symptoms, such as itchy eyes and congested sinuses, I constantly felt lethargic and lacking in energy; like I’d been sedated. My hay fever was sometimes so bad that I had to be sent home from work. As well as trying antihistamines (both tablet and nasal formulations), he even resorted to alternative treatments such as acupuncture. But nothing helped. And over time his symptoms actually got worse. – My hay fever took a turn for the worse five years ago, when the severity of my symptoms increased. The worst experience occurred when I was on holiday in France. I woke up in the middle of the night with the horrible feeling that I was going to die, unable to catch my breath. The only thing I could do to ease the symptoms was to get in the car and turn the air conditioning on to clear my airways of pollen. The following day, David headed straight back home to London and his doctor, who promised David that he would endeavour to find a more efficient treatment than antihistamines. And at the end of 2003, David was able to take part in an allergy vaccine trial. After a skin-prick test, he was diagnosed with an allergy to grass pollen. The treatment needed to be started straight away, outside of the pollen season. After a number of tests, David was prescribed ALK’s allergy vaccine Alutard SQ®. – Now that I am receiving allergy vaccination, most of my hay fever symptoms have disappeared. The severity of the remaining symptoms is about one fifth of what it used to be. During last summer, I only took a total of 10 antihistamines, whereas prior to the treatment, I had to take them every day. Surprised friends and family have also remarked on my transformation during the hay fever season. Because I’m not tired and lethargic, I’m free to be myself – a bubbly, loud and outgoing person. It is the effective allergy treatment that has given me that freedom.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=24http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=2424 ALK Fighting the cause of allergy Allergic to stagnation? Find new challenges in a growing, innovative company and join more than 1,400 colleagues striving to improve quality of life for people with allergy ALK is the world’s leading company within specific allergy treatment, but we have managed to maintain our pioneering spirit. We are large enough to offer you challenges and good opportunities for development, but you will not disappear in the crowd. We have experienced success and significant growth in recent years, and we are in the middle of an exciting process of developing and professionalising our working procedures and entering new markets. In relation to this process, we have a need for employees that both desire and are capable of influencing the company. Therefore, we give you space to fully apply and unfold your talents. Visit www.alk-abello.com to find open positions. Number of employees 2001-2007 1500 1400 1300 1200 1100 1000 ALK employee survey Top 5 1. “My department produces results” 2. “I think the ALK Group will develop positively” 3. “I know which goals I am expected to achieve” 4. “I have capable colleagues in my department” 5. “The ALK Group’s pipeline of new and improved products secures our future” 89% 88% 87% 87% 85% 1432 Percentage of employees who ‘agrees’ or ‘completely agrees’ 2001 2002 2003 2004 2005 2006 20072008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=25http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=25ALK Fighting the cause of allergy 25 ALK’s four values: Progressive, Focused, United, Trustworthy “As an HR Consultant, being focused means giving my full attention to the candidates I’m interviewing” Marianne Beck, HR Business Partner, ALK2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=26http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=2626 ALK Fighting the cause of allergy Pioneering allergy vaccination since 1923 1923 1923 Doctor Kaj Hedemann Baagøe and pharmacist Poul Christian Krejner Tejn Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at the Copenhagen University Hospital (Rigshospitalet). In 1928, production of allergy vaccines and diagnostics is moved to Frihavns Pharmacy. 1972 Doctor Bent Weeke and chemist Henning Løwenstein develop the technique known as ‘Crossed Radio Immuno Electrophoresis’, which makes it possible to very accurately identify the proteins that provoke allergies in individual patients. The results lay the foundations for a standardisation of allergy vaccines and are presented at the European Allergy Congress in Oslo in 1972. 1949 1978 Allergology Laboratory markets the first standardised allergy vaccine under the Alutard SQ® brand (SQ stands for Standardised Quality). 1984 The sales company ALK America Inc. is founded in the United States. In 1985, Allergology Laboratory is approved by the US health authorities (FDA). 1949 Production of allergy vaccines and diagnostics is separated from Frihavns Pharmacy to become an independent unit called Allergologisk Laboratorium (Allergology Laboratory), which becomes a public limited company in 1961. 1976 ‘Danish Allergen Standardisation 1976 (DAS 76)’ is completed on the basis of Løwenstein and Weeke’s techniques. The collaborative project enables Allergology Laboratory – as the first in the world – to distinguish and standardise allergen extracts. 1986 Allergology Laboratory officially changes its name to ALK (Allergologisk Laboratorium København) and, in 1987, moves to the science park in Hørsholm, Denmark.2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=27http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=27ALK Fighting the cause of allergy 27 1972 1976 1978 1984 1986 1990 1992 1998 2006 2007 1990 Abelló S.A. launches the first product for sublingual allergy vaccination (droplets administered under the tongue) in Southern Europe. 1992 ALK acquires its largest competitor ‘Alergia e Inmunologia Abelló S.A.’ headquartered in Madrid. 2006-08 ALK launches GRAZAX® – the world’s first registered tablet-based allergy vaccine. 1992 The PAT (Preventative Allergy Treatment) study is initiated in collaboration with leading European allergy specialists. The study finds that allergy vaccination prevents the development of asthma. 1998 WHO, the World Health Organisation, recommends allergy vaccination in a Position Paper. 2003 ALK launches SLITone® – the world’s first sublingual allergy vaccine in single dose containers. 2008 20032008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=28http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=2828 ALK Fighting the cause of allergy “A summer without allergy gives me more freedom and energy. Everything is easier and more fun” Anders Ohlin, Sweden2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=29http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=29ALK Fighting the cause of allergy 292008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=30http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=3030 ALK Fighting the cause of allergy Abbreviated summary of product characteristics Product information for GRAZAX®. Pharmaceutical form and composition: GRAZAX® are oral lyophilisates (tablets) for specific immunotherapy that contain SQ standardized allergen extracts of Timothy grass pollen (Phleum pratense) at a concentration of 75,000 SQ-T per tablet. Therapeutic indications: Grass pollen induced rhinitis and conjunctivitis in adults with clinically significant symptoms and a positive skin prick test and/or specific IgE test to grass pollen. Posology and method of administration: The daily dose is one tablet to be placed under the tongue. Avoid swallowing for about 1 minute. Start treatment at least 2 months prior to the expected start of the grass pollen season and continue treatment throughout the grass pollen season. First tablet is recommended to be taken under medical supervision (20–30 minutes).Contraindications: Hypersensitivity to excipients, malignancy or systemic diseases affecting the immune system, inflammatory conditions in the oral cavity with severe symptoms, and patients with uncontrolled or severe asthma. Special warnings and precautions for use: Oral surgery, asthma deterioration. Interaction with other medicinal products and other forms of interaction: Concomitant therapy with symptomatic anti-allergic agents (e.g. antihistamines, corticosteroids and mast cell stabilisers) may increase the tolerance level of the patient to immunotherapy. No data on possible risks of simultaneous immunotherapy with other allergens. Pregnancy and lactation: No clinical experience. Animal studies do not indicate increased risk. Treatment should not be initiated during pregnancy. Undesirable effects: Primarily mild to moderate local allergic reactions are to be expected (in studies, 70% of patients). In the majority of patients the reactions start early in therapy, last from minutes to hours and tend to subside spontaneously within 1 to 7 days. If the patient experiences significant adverse events, anti-allergic medication should be considered. In cases of severe systemic reactions, angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, feeling of fullness in the throat or asthma deterioration, a physician should be contacted immediately. Overdose: Doses up to 1,000,000 SQ-T have been tolerated. Excipients: Gelatin (fish source), mannitol, sodium hydroxide. Shelf life: 2½ years. Content of container: Aluminium blister cards with 30 or 100 tablets. Marketing authorisation holder: ALK-Abelló A/S, Bøge Alle 6-8, DK-2970 Hørsholm, Denmark. Marketing authorisation number: 21278. Product information for SLITone ®. Pharmaceutical form and composition: SLITone® are sublingual formulations for specific immunotherapy containing standardized allergen extracts as the active substance. The biological activity of the allergen in SLITone® is expressed in STU (Specific Treatment Units). Therapeutic indications: Specific immunotherapy treatment of IgE-mediated allergy. Posology and method of administration: The solution (one container) should be administered once daily and applied directly under the tongue (sublingually) from the single dose container and kept for at least 2 minutes before swallowing. Food and beverage should not be taken for the following 5 minutes. Treatment duration for at least 3 years. Contraindications: Systemic diseases strongly affecting the immune system, e.g. immune complex diseases and immune deficiency diseases. Hypersensitivity to any of the excipients of the solution. Special warnings and precautions for use: Inflammatory conditions in the oral cavity with severe symptoms, e.g. oral lichen planus with ulcerations or severe oral mycosis. Oral surgery including dental extractions. Interactions: Concomitant therapy with symptomatic anti-allergic agents (e.g. antihistamines, corticosteroids and mast cell stabilizers) may increase the tolerance level of the patient to immunotherapy. Adverse 2008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=31http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=31ALK Fighting the cause of allergy 31 ALK addresses E W mailbox@alk-abello.com alk-abello.com DEnmARK ALK Headquarters: Bøge Allé 6-8 DK-2970 Hørsholm T +45 45 74 75 76 F +45 45 74 86 90 Sales office: Fruebjergvej 3 Postboks 80 DK-2100 København Ø T +45 38 16 70 70 F +45 38 16 70 99 GERmAny Feldstraße 170 D-22880 Wedel T +49 41 03 70 17 0 F +49 41 03 70 17 788 SWITZERLAnD Industriestrasse 30 CH-8604 Volketswil T +41 44 908 21 00 F +41 44 908 21 09 ITALy Via Ramazzotti 12 I-20020 Lainate MI T +39 02 93 7631 F +39 02 93 763457 UK 1 Tealgate Hungerford, Berkshire RG17 OYT T +44 1488 68 60 16 F +44 1488 68 54 23 AUSTRIA Bäckermühlweg 59 A-4030 Linz T +43 732 385 372 F +43 732 385 37 277 THE nETHERLAnDS Edisonbaan 26 Postbus 1041 NL-3430 BA Nieuwegein T +31 30 600 5 790 F +31 30 600 5 792 USA Main office: 1700 Royston Lane Round Rock, Texas 78664 T +1 512 251 0037 F +1 512 251 8450 Manufacturing: 35 Channel Drive Port Washington, New York 10050 T +1 516 767 1800 F +1 516 767 4229 Source materials: 1095 Upper Georges Valley Rd Spring Mills, PA 16875 T +1 814 422 8165 F +1 814 422 8424 Source materials: 327 East Pacific Avenue Spokane WA 99202 T +1 509 456 7794 F +1 509 455 7965 CHInA Rm 1502-3, 15/F, Metropole Square 2 on Yiu Street Shatin, Hong Kong T +852 2144 5218 F +852 2144 5618 nORWAy Industriveien 23 B NO-2050 Jessheim T +47 6394 6040 F +47 6394 6041 FInLAnD Spektrin Kvartti Metsänneidonkuja 10 FI-02130 Espoo T +358 9 7255 5320 F +358 9 7255 5321 POLAnD ul. Duchnicka 3 PL-01-796 Warszawa T +48 22 832 09 15 F +48 22 639 87 94 FRAnCE Main office: 7, Place de la Défense FR-92400 Courbevoie T +33 1 41 02 86 86 F +33 1 41 02 86 69 Manufacturing: FR-55271 Varennes-en-Argonne Cedex T +33 3 29 80 71 62 F +33 3 29 80 78 34 Manufacturing: 5 route de Breuil FR-51140 Vandeuil T +33 3 26 05 32 41 F +33 3 26 07 77 68 SPAIn Miguel Fleta 19 E-28037 Madrid T +34 91 32 76 100 F +34 91 32 76 122 SWEDEn P.O. Box 10073 SE-434 21 Kungsbacka T +46 30 01 85 45 F +46 30 01 39 102008-06-27T14:04:42+02:00http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=32http://nozebra.ipapercms.dk/alk/uk/CorporateBrochure2008/?Page=32ALK · Bøge Allé 6-8 · DK–2970 Hørsholm, Denmark · Tel. +45 45 74 75 76 · www.alk-abello.com2008-06-27T14:04:42+02:00